Extended Dual Versus Single Anti‐Platelet Therapy Following Percutaneous Coronary Intervention: A Bayesian Meta‐Analysis and Regression on All‐Cause Mortality
Catheterization and Cardiovascular Interventions · 2026
DOI: 10.1002/ccd.70363 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Catheterization and Cardiovascular Interventions, 2026. Verfasst von Faizan Ahmed und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Jersey Shore University Medical Center, Hackensack Meridian Health, Neptune, New Jersey, USA. Hauptthemen laut MEDLINE: Platelet Aggregation Inhibitors, Percutaneous Coronary Intervention, Dual Anti-Platelet Therapy, Coronary Artery Disease. Die Arbeit nennt 49 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Introduction
Current ESC/EACTS guidelines recommend standard‐duration dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI). However, the subsequent transition to either extended DAPT or single antiplatelet therapy (SAPT) remains debated due to limited comparative outcome data. This Bayesian meta‐analysis and meta‐regression evaluate the clinical safety of DAPT versus SAPT, and the impact of potential confounders on all‐cause mortality.
Methods
Following PRISMA guidelines, a systematic search of PubMed, Embase, Cochrane Library, ScienceDirect, and Scopus was conducted till April 2025 to identify randomized clinical trials (RCTs) and cohort studies. Primary outcomes were all‐cause mortality and bleeding events. Bayesian random‐effects meta‐analysis was performed using the brms package in R with Markov Chain Monte Carlo sampling and weakly informative priors. Bayesian meta‐regression of log‐transformed odds ratios (OR) assessed associations with relevant covariates.
Results
Fourteen studies (9 RCTs and 5 cohort studies) comprising 56,572 patients were included. Compared with SAPT, DAPT was associated with increased all‐cause mortality (OR 1.25; 95% credible interval [CrI], 1.04–1.51; posterior probability of harm, Pr[OR > 1] = 84%). DAPT also increased the risk of net adverse clinical events [NACE] (OR, 1.29; 95% CrI, 1.08–1.53), minor bleeding (OR, 1.60; 95% CrI, 1.10–2.33), major bleeding (OR, 1.70; 95% CrI, 1.30–2.23), and BARC 2–5 bleeding (OR, 1.78; 95% CrI, 1.40–2.26) with Pr [OR > 1] >90% for all outcomes. No significant differences were observed in cardiac death, cardiovascular mortality, major adverse cardiac and cerebrovascular events (MACCE), myocardial infarction (MI), stent thrombosis, or stroke. Meta‐regression revealed that higher baseline odds of dyslipidemia (−0.89), hypertension (−1.19), prior MI (−0.94), and previous revascularization (−0.30) were associated with greater mortality benefit from DAPT. However, in the DAPT cohort, increased odds of adverse events, including cardiac death (0.41), MACCE (0.55), stroke (0.60), MI (0.29), and NACE (0.98), were significantly associated with higher all‐cause mortality.
Conclusion
Extended DAPT is associated with a higher all‐cause mortality, bleeding events, and NACE. While DAPT may benefit high‐risk populations, the increased odds of adverse events are significantly associated with mortality, warranting that it be carefully considered and monitored in post‐PCI patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Jersey Shore University Medical Center, Hackensack Meridian Health, Neptune, New Jersey, USA.
- Allama Iqbal Medical College, Lahore, Pakistan.
- Peoples University of Medical & Health Sciences, Nawabshah, Pakistan.
- Sheikh Zayed Medical College, Rahim Yar Khan, Pakistan.
- Ameer-ud-Din Medical College, Lahore, Pakistan.
- King Edward Medical University, Lahore, Pakistan.
ORCID-Profile: Muhammad Arham, Zuha Tariq, Ahsan Alam, Muhammad Usman, Tehmasp Rehman Mirza, Ameer Haider Cheema
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Ahmed, F., Haider, F., Ali, R., Arham, M., Gohar, N., Batool, A., Sharif, S., Khan, M. H. A., Tariq, Z., Shah, S. S., Ullah, A., Alam, A., Hamdani, S. S. Q., Usman, M., Mirza, T. R., Sattar, Y., Patel, S., Almendral, J., Cheema, A. H., & Alenezi, F. (2026). Extended Dual Versus Single Anti‐Platelet Therapy Following Percutaneous Coronary Intervention: A Bayesian Meta‐Analysis and Regression on All‐Cause Mortality. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70363
Vancouver
Ahmed F, Haider F, Ali R, Arham M, Gohar N, Batool A, et al. Extended Dual Versus Single Anti‐Platelet Therapy Following Percutaneous Coronary Intervention: A Bayesian Meta‐Analysis and Regression on All‐Cause Mortality. Catheterization and Cardiovascular Interventions. 2026. doi:10.1002/ccd.70363
BibTeX
@article{Ahmed2026,
author = {Ahmed, Faizan and Haider, Faseeh and Ali, Ramsha and Arham, Muhammad and Gohar, Najam and Batool, Ayesha and Sharif, Sara and Khan, Muhammad Huzaifa Ahmed and Tariq, Zuha and Shah, Syeda Simrah and Ullah, Aman and Alam, Ahsan and Hamdani, Syed Shah Qasim and Usman, Muhammad and Mirza, Tehmasp Rehman and Sattar, Yasar and Patel, Swapnil and Almendral, Jesus and Cheema, Ameer Haider and Alenezi, Fawaz},
title = {Extended Dual Versus Single Anti‐Platelet Therapy Following Percutaneous Coronary Intervention: A Bayesian Meta‐Analysis and Regression on All‐Cause Mortality},
journal = {Catheterization and Cardiovascular Interventions},
year = {2026},
doi = {10.1002/ccd.70363}
}
EUVIMED